Abstract
Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 675-677 |
| Number of pages | 3 |
| Journal | Nature medicine |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2007 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)